ReviewEye (London, England)2018
Neuroprotective agents in the management of glaucoma.
Review in Eye (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Genome-wide meta-analysis identifies 22 loci for normal tension glaucoma with significant overlap with high tension glaucoma.Nature communications · 2024Pooled it
- Pooled it
- Cyclic stretch increases transglutaminase 2-mediated serotonylation of extracellular fibronectin in cultured optic nerve head astrocytes: a pilot study.Matrix biology plus · 2026Article
- Dual-functional nanoparticle formulations for simultaneous intraocular pressure reduction and neuroprotection in glaucoma: a review.Nanomedicine (London, England) · 2026Review
- Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Next-Gen Neuroprotection in Glaucoma: Synergistic Molecules for Targeted Therapy.Journal of clinical medicine · 2025Review
- From a Fish Protein to a Novel Glaucoma Therapeutic: Stanniocalcin-1 for Intraocular Pressure Reduction.Advances in ophthalmology and optometry · 2025Article
- Genetic prioritisation of candidate drug targets for glaucoma through multi-trait and multi-omics integration.Eye and vision (London, England) · 2025Article
- Exploring the impact of diet, sleep, and metabolomic pathways on Glaucoma subtypes: insights from Mendelian randomization and cross-sectional analyses.Nutrition & metabolism · 2025Article
- Identifying diagnostic biomarkers for glaucoma based on transcriptome combined with Mendelian randomization.Scientific reports · 2025Article
- Exploring Glaucoma: From Pathogenesis to Emerging Diagnostic and Management Strategies.Journal of ophthalmology · 2025Review
- Neuritin: a multifaceted neuroprotective factor with emerging applications for neurodegeneration.Frontiers in neuroscience · 2025Review
- Evolutionary medicine and bioastronautics: an innovative approach in addressing adverse mental health effects to astronauts during long term space missions.Frontiers in physiology · 2025Article
- Research on neurotrophic factor for glaucoma: a worldwide bibliometric analysis.International journal of ophthalmology · 2025Article
- Dysregulation of neuroprotective lipoxin pathway in astrocytes in response to cytokines and ocular hypertension.Acta neuropathologica communications · 2024Article
- Navigating the Unknown: A Comprehensive Review of Spaceflight-Associated Neuro-Ocular Syndrome.Cureus · 2024Review
- Neuroprotective effect of mesenchymal stem cell-derived extracellular vesicles on optic nerve injury in chronic ocular hypertension.Neural regeneration research · 2023Article
- Therapeutic Potential of Cannabinoids in Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Proteomics-Based Identification of Retinal Protein Networks Impacted by Elevated Intraocular Pressure in the Hypertonic Saline Injection Model of Experimental Glaucoma.International journal of molecular sciences · 2023Article
- Fluoxetine Protects Retinal Ischemic Damage in Mice.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is an optic neuropathy, specifically a neurodegenerative disease characterized by loss of retinal ganglion cells (RGCs) and their axons. The pathogenesis of RGC loss in glaucoma remains incompletely understood and a broad range of possible mechanisms have been implicated. Clinical evidence indicates that lowering intraocular pressure (IOP) does not prevent progression in all patients; therefore, risk factors other than those related to IOP are involved in the disease. The need for alternative, non-IOP-lowering treatments focused at preventing progression, that is, neuroprotectants, has become of interest to both the patient and the physician. Experimental evidence accumulated during the past two decades lend a great deal of support to molecules endowed with neuroprotective features. However, translation to the clinic of the latter drugs results unsuccessful mostly because of the lack of reliable in vivo measure of retinal damage, thus hampering the good therapeutic potential of neuroprotective agents given alone or as adjuvant therapy to IOP-lowering agents. Further research effort is needed to better understand the mechanisms involved in glaucoma and the means to translate into clinic neuroprotective drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.